Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether droxidopa, a medication that increases
norepinephrine levels, may be effective in improving some aspects of cognition and movement
in Parkinson's disease (PD).